HKU Medicine completes Asia's first kidney cancer cases using tissue fragmentation technique
HKU Medicine has performed Asia's first two kidney cancer surgeries using tissue fragmentation technology, allowing patients to retain their kidneys. The non-invasive, radiation-free procedure takes one hour, with one patient reporting normal meals on the day of surgery and only mild blood in urine.
The University of Hong Kong's Faculty of Medicine (HKU Medicine) has successfully completed two cases of early-stage kidney cancer treatment using tissue fragmentation technology, marking the first such procedures in Asia. Both patients were able to preserve their kidneys following the surgery.
One patient, identified only as Mr Lee, said he underwent the operation last month. He reported being able to eat normal meals by lunch and dinner on the day of the procedure, experienced no pain afterwards, and only noticed some blood in his urine.
Professor Terence Chisan Cheng, Clinical Professor in the Department of Surgery, School of Clinical Medicine at HKU Medicine, explained that the tissue fragmentation technique involves doctors controlling the emission of ultrasonic energy, which is precisely directed at the kidney tumour. The surgery takes approximately one hour. He highlighted that the procedure is non-invasive, involves no incisions and does not expose the patient to radiation.
Professor Cheng noted that HKU Medicine first introduced this technology for treating liver cancer in 2024, and subsequently applied the same technique to pancreatic cancer. To date, the faculty has completed 20 cases. Research is focused on accurately targeting the appropriate areas of the pancreas, and the team has already acquired the necessary skills. A research report is expected to be published shortly.
Dr Leo Leung, Clinical Assistant Professor in the Department of Surgery, School of Clinical Medicine at HKU Medicine, said that the tissue fragmentation technique is currently suitable only for treating early-stage kidney cancer, as it remains in the clinical trial phase. Early-stage kidney tumours are smaller and easier to treat. The main side effect is blood in the urine, which typically resolves within one to two days after surgery. Dr Leung added that it is possible that as the technology matures, it could be extended to treat other types of cancer.